Atrial Fibrillation Devices Market Report 2025

The atrial fibrillation devices market size has grown rapidly in recent years. It will grow from $7.69 billion in 2024 to $8.6 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth during the historic period can be attributed to an increase in the aging population, rising demand for minimally invasive cardiac procedures, expansion of government initiatives, and greater availability of telecardiology services.

The atrial fibrillation devices market size is expected to see rapid growth in the next few years. It will grow to $13.28 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth during the forecast period can be attributed to rising healthcare expenditure, an increasing number of multi-specialty hospitals, greater adoption of advanced treatment options, enhanced regulatory support for device approvals, and growing demand for minimally invasive surgical procedures. Key trends anticipated in the forecast period include technological advancements, progress in remote monitoring devices, integration of artificial intelligence in diagnostic processes, innovations in minimally invasive ablation systems, and improvements in mapping and imaging technologies.

The increasing burden of cardiovascular diseases is expected to drive the growth of the atrial fibrillation device market in the coming years. Cardiovascular diseases encompass conditions that affect the heart and blood vessels, such as heart attacks, strokes, and hypertension. The growing prevalence of these conditions is largely attributed to rising global rates of obesity and diabetes, combined with sedentary lifestyles and unhealthy eating habits. Atrial fibrillation (AFib) devices are essential for managing cardiovascular diseases by detecting, monitoring, and treating irregular heart rhythms, which are frequently linked to underlying heart problems. For example, in June 2024, the American Heart Association, a US-based public health organization, reported that as the prevalence of high blood pressure is projected to increase from 51.2% to 61%, the number of individuals diagnosed with cardiovascular diseases is expected to grow from 128 million in 2020 to over 184 million by 2050. Thus, the rising incidence of cardiovascular diseases is contributing to the expansion of the atrial fibrillation device market.

Key players in the atrial fibrillation devices market are focusing on technological advancements, such as patient-centric clinical decision support tools, to improve diagnostic accuracy, customize treatment strategies, and enhance patient outcomes. These tools are digital systems designed to assist healthcare providers by analyzing individual patient data to inform more personalized care decisions. For instance, in August 2023, GE HealthCare Technologies Inc., a US-based medical technology company, introduced CardioVisio for Atrial Fibrillation, a digital clinical decision support tool created to streamline clinician workflows and support targeted care for AFib patients. The tool helps visualize AFib progression, incorporating previous diagnoses, treatments, medications, and related conditions. It also provides therapy recommendations based on established guidelines, reducing the likelihood of diagnostic errors and facilitating more efficient clinical decision-making. CardioVisio consolidates scattered patient data into an accessible format, helping medical professionals manage atrial fibrillation more effectively and efficiently.

In November 2023, Johnson & Johnson MedTech, a US-based medical technology firm, acquired Laminar Inc. for an undisclosed amount. This acquisition aims to enhance Johnson & Johnson MedTech’s position in the atrial fibrillation device sector and broaden its range of solutions focused on stroke prevention and cardiac care. Laminar Inc. is a US-based company specializing in the development of innovative devices for left atrial appendage elimination, which are used to prevent strokes in patients with atrial fibrillation.

Major players in the atrial fibrillation devices market are Johnson & Johnson Services Inc., Abbott Laboratories, Medtronic Public Limited Company, Koninklijke Philips N.V., Boston Scientific Corporation, Shanghai MicroPort EP MedTech Co. Ltd., Japan Lifeline Co. Ltd., Microlife Corporation, AliveCor Inc., CardioFocus Inc., Imricor Medical Systems Inc., Kardium Inc., Stereotaxis Inc., Volta Medical, Synaptic Medical Corporation, Osypka AG, CathRx Ltd., BIOTRONIK SE & Co. KG, EP Solutions SA, CardiacSense Ltd.

North America was the largest region in the atrial fibrillation devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in atrial fibrillation devices report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the atrial fibrillation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The atrial fibrillation devices market consists of revenues earned by entities providing services such as diagnostic services, therapeutic services, and patient monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The atrial fibrillation devices market also includes sales of cryoablation catheters, laser ablation systems, and hybrid ablation systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The atrial fibrillation devices market research report is one of a series of new reports that provides atrial fibrillation devices market statistics, including atrial fibrillation devices industry global market size, regional shares, competitors with a atrial fibrillation devices market share, detailed atrial fibrillation devices market segments, market trends and opportunities, and any further data you may need to thrive in the atrial fibrillation devices industry. This atrial fibrillation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Atrial fibrillation (AFib) devices are medical technologies developed to detect, monitor, or treat atrial fibrillation, a prevalent heart rhythm disorder characterized by irregular beating of the heart’s upper chambers. These devices include implantable cardiac monitors, pacemakers, defibrillators, catheter ablation systems, and wearable electrocardiogram (ECG) monitors. The primary objective of AFib devices is to restore normal heart rhythm, minimize stroke risk, and enhance quality of life.

The main types of atrial fibrillation devices include implantable devices, external devices, and catheter-based devices. Implantable devices refer to tools such as pacemakers, implantable cardioverter defibrillators (ICDs), and implantable loop recorders, which are surgically placed within the body to monitor, regulate, or correct heart rhythm by delivering electrical impulses or continuously recording cardiac activity. These devices are used across various applications, including electrophysiology ablation catheters, cardiac monitors or implantable loop recorders, electrophysiology diagnostic catheters, mapping and recording systems, access devices, intracardiac echocardiography, left atrial appendage closure devices, and other related tools. They operate using technologies such as radiofrequency, cryotherapy, ultrasound, and other advanced methods. Distribution channels include direct sales, distributors, and online platforms, serving end users such as hospitals, cardiac centers, ambulatory surgical centers, and other healthcare providers.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.